Your browser doesn't support javascript.
loading
[Family with marked hyperferritinemia as a result of hemochromatosis type 4 (ferroportin disease)]. / Familie mit ausgeprägter Hyperferritinämie als Folge einer Hämochromatose Typ 4 (Ferroportin-Krankheit).
Muehlenberg, K; Faltermeier, N; Lohse, P; Tannapfel, A; Pech, O.
Afiliação
  • Muehlenberg K; Klinik für Gastroenterologie und interventionelle Endoskopie, Akademisches Lehrkrankenhaus Universität Regensburg, Krankenhaus Barmherzige Brüder, Regensburg.
  • Faltermeier N; Klinik für Gastroenterologie und interventionelle Endoskopie, Akademisches Lehrkrankenhaus Universität Regensburg, Krankenhaus Barmherzige Brüder, Regensburg.
  • Lohse P; Institut für Laboratoriumsmedizin und Molekulargenetik, Singen.
  • Tannapfel A; Ruhr-Universität Bochum, Institut für Pathologie, Bochum.
  • Pech O; Klinik für Gastroenterologie und interventionelle Endoskopie, Akademisches Lehrkrankenhaus Universität Regensburg, Krankenhaus Barmherzige Brüder, Regensburg.
Z Gastroenterol ; 52(9): 1075-80, 2014 Sep.
Article em De | MEDLINE | ID: mdl-25198087
Iron overload in MR-imaging with decreased signal intensity in T2 weighting of liver, spleen, adrenal gland and pituitary gland in combination with an extremely elevated ferritin level of 9859  ng/mL and a positive family history of hyperferritinaemia led to the diagnosis of the rare hemochromatosis type 4 (synonym: ferroportin disease) in the case of a 62-year-old patient. The autosomal dominant disease was confirmed by analysis of the SLC40A1-gene. Histologically, a liver cirrhosis was detected. This was neither detectable in the case of the two similarly aged cousins (ferritin about 4750  ng/mL, transferrin saturation normal), nor in the case of the 82-year-old mother (ferritin 7860  ng/dL, transferrin saturation 58 %). Hemochromatosis type 4 with worldwide less than 200 described cases is caused by a disorder of the hepcidin ferroportin metabolism, which regulates the iron export from the cells. A hepatocellular carcinoma may occur even without cirrhosis. Therefore, surveillance of these patients is necessary. Treatment options are therapeutic phlebotomies and alternatively iron-chelating drugs (Deferoxamin, Deferasirox) if the patient develops anaemia.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Catarata / Distúrbios do Metabolismo do Ferro / Hemocromatose Tipo de estudo: Diagnostic_studies Limite: Aged80 / Female / Humans / Male / Middle aged Idioma: De Revista: Z Gastroenterol Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Catarata / Distúrbios do Metabolismo do Ferro / Hemocromatose Tipo de estudo: Diagnostic_studies Limite: Aged80 / Female / Humans / Male / Middle aged Idioma: De Revista: Z Gastroenterol Ano de publicação: 2014 Tipo de documento: Article